U01CA265739

Comparative Modeling for the Prevention and Control of Uterine Cancer

Uterine cancer is the 4th most common cancer in women and the 7th most frequent cause of cancer-related death. The death rate from uterine cancer is rising faster than for any other tumor. Importantly, uterine cancer is associated with a profound racial disparity. Compared to white women, black women are significantly more likely to die from uterine cancer, and this disparity is increasing.

The overarching goal of this proposal is to inform cancer control and prevention strategies to reduce the incidence and mortality of uterine cancer by improving the prevention, screening, and treatment of the disease. We will accomplish this goal through a collaborative modeling consortium in which three groups develop natural history models of uterine cancer. These models will incorporate known risk factors for uterine cancer and population-level changes in the prevalence of these risk factors over time. The models will include pathways for both favorable prognosis (Type I) uterine cancer as well as more aggressive (Type II) neoplasms.

Once developed and validated, we will perform comparative modeling to examine issues of importance to clinicians and policymakers. First, we will examine currently available and emerging strategies for screening and prevention of uterine cancer in women. Second, we will examine the harms, benefits, and cost-effectiveness of treatment strategies for uterine cancer, including adjuvant therapy, treatment of metastatic disease, and treatment of recurrent disease, including immunotherapy. Third, we will estimate how changing epidemiologic factors and social determinants of health influence racial disparities for uterine cancer. Fourth, we will explore the impact of the rising rate of obesity on the incidence and mortality of uterine cancer and develop novel, web-based tools to determine how state-level obesity control activities influence incidence and mortality. Finally, we will explore how the declining hysterectomy rate and changing patterns of care for gynecologic diseases influence uterine cancer incidence and mortality.

At the completion of this work, these data will be widely disseminated to patients, providers, and policymakers and have the potential to significantly impact the clinical care of women with uterine cancer and to guide cancer control strategies. Furthermore, these models will serve as an invaluable resource for the uterine cancer community as new clinical questions and challenges emerge.

The Trustees Of Columbia University In The City Of New York

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

New York, New York 100323720 United States

Single Zip Code

Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01 Clinical Trial Not Allowed) (RFA-CA-20-043)

Amendment Since initial award the total obligations have increased 340% from $947,887 to $4,171,414.